Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma

Published:2012-04-16 Issue:11 Volume:47 Page:1397-1402
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Bethge W A,von Harsdorf S,Bornhauser M,Federmann B,Stelljes M,Trenschel R,Baurmann H,Dittmann H,Faul C,Vogel W,Kanz L,Bunjes D

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt201262.pdf

Reference39 articles.

1. Hamadani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P et al. Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant 2009; 15: 547–553.

2. Peniket AJ, Ruiz De Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667–678.

3. Tse WW, Lazarus HM, Van Besien K . Stem cell transplantation in follicular lymphoma: progress at last? Bone Marrow Transplant 2004; 34: 929–938.

4. Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK . Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma. Blood 1997; 90: 4201–4205.

5. Sandmaier BM, McSweeney P, Yu C, Storb R . Nonmyeloablative transplants: preclinical and clinical results. Semin Oncol 2000; 27: 78–81.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioligand Therapy in Lymphoma;PET Clinics;2024-10

2. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-09

3. Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting;Seminars in Nuclear Medicine;2022-03

4. Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma;Blood Advances;2021-12-30

5. Theranostics of Hematologic Disorders;Nuclear Medicine and Immunology;2021-11-25